Abacavir-Lamivudine (Epzicom)

Table of Contents

- Abacavir-Lamivudine Epzicom Editor's Summary
- Drug Summary
- Guidelines for use in Antiretroviral-Naïve Patients
- Key Clinical Trials
- Adverse Effects
- Use In Pregnancy
- Resistance
- Key Drug Interactions

Drug Summary

Abacavir-lamivudine has played a significant role as a nucleoside reverse transcriptase inhibitor (NRTI) backbone in antiretroviral regimens. The primary current uses for abacavir-lamivudine are (1) as part of the highly effective single tablet regimen dolutegravir-abacavir-lamivudine and (2) as an alternative to tenofovir DF-emtricitabine in patients with renal insufficiency or osteoporosis. For patients with a baseline HIV RNA level greater than 100,000 copies/mL, the abacavir-lamivudine NRTI backbone should be avoided if used with efavirenz, raltegravir, atazanavir boosted with cobicistat or ritonavir. A life-threatening abacavir hypersensitivity reaction can occur in individuals who are HLA-B*5701 positive. Thus, all patients need to undergo testing for HLA-B*5701 prior to receiving abacavir and those who test positive for HLA-B*5701 should not take abacavir. Several studies have suggested that abacavir may increase the risk of ischemic cardiovascular events, but the data overall have been inconclusive. Nevertheless, based on available information, most experts avoid the use of abacavir in patients with ischemic cardiovascular disease if effective alternatives exist. The dose of abacavir should be reduced for patients with mild hepatic impairment (Child-Turcotte-Pugh class A cirrhosis) and the medication should be avoided in the setting of more advanced impairment (Child-Turcotte-Pugh class B or C cirrhosis). Lamivudine requires adjustment of dosage in patients with a creatinine clearance less than 50 mL/min.

Guidelines for use in Antiretroviral-Naïve Patients

In the October 17, 2017 version of the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, abacavir-lamivudine is designated as listed below for treatment-naïve patients:

Recommended Initial Regimens for Most People with HIV

- Dolutegravir-abacavir-lamivudine—if HLA-B*5701 negative (AI)
**Recommended Initial Regimens in Certain Clinical Situations**

- Darunavir-cobicistat plus **abacavir-lamivudine**—if HLA-B*5701 negative (BII)
- Darunavir plus ritonavir plus **abacavir-lamivudine**—if HLA-B*5701 negative (BII)
- Atazanavir-cobicistat plus **abacavir-lamivudine**—if HLA-B*5701 negative and HIV RNA less than 100,000 copies/mL (CIII)
- Atazanavir plus ritonavir plus **abacavir-lamivudine**—if HLA-B*5701 negative and HIV RNA less than 100,000 copies/mL (CII)
- Raltegravir plus **abacavir-lamivudine** (CII)—if HLA-B*5701–negative and HIV RNA less than 100,000 copies/mL

---

**Key Clinical Trials**

Abacavir-lamivudine and tenofovir disoproxil fumarate (DF)-emtricitabine had comparable virologic efficacy when either was combined with lopinavir-ritonavir [HEAT] or darunavir plus ritonavir [FLAMINGO]. In contrast, abacavir-lamivudine had inferior virologic response compared with tenofovir DF-emtricitabine when both were given with efavirenz [ASSERT]. In a trial that randomized participants to abacavir-lamivudine or tenofovir DF-emtricitabine, combined with efavirenz or ritonavir-boosted atazanavir, virologic outcomes were inferior for those receiving abacavir-lamivudine if the baseline HIV RNA level was greater than 100,000 copies/mL [ACTG 5202]. However, participants in a trial of abacavir-lamivudine plus dolutegravir [SINGLE] versus abacavir-lamivudine plus ritonavir boosted darunavir had excellent virologic responses, even with baseline HIV RNA levels greater than 100,000 copies/mL. Screening for HLA-B*5701 prior to initiating abacavir markedly reduces the risk of persons developing the abacavir hypersensitivity reaction [PREDICT-1].

---

**Adverse Effects**

Lamivudine is very well tolerated and infrequently causes any adverse effects. Hyperpigmentation of the palms and soles has been reported with lamivudine and the risk is higher in persons with darker pigmented skin. Abacavir can cause a life-threatening hypersensitivity reaction; this reaction manifests as flu-like symptoms with or without rash and gastrointestinal symptoms, all of which worsen with each dosage. The abacavir hypersensitivity reaction may occur in individuals who are positive for HLA-B*5701. Screening for HLA-B*5701 should be done before initiating abacavir; avoidance of abacavir in persons who are positive for HLA-B*5701 eliminates the occurrence of immunologically confirmed hypersensitivity. Other possible side effects include rash, malaise, fatigue, anxiety, and elevations in hepatic aminotransferase levels. Some clinical trials have shown that abacavir leads to an increased risk of ischemic cardiovascular events, while other trials have failed to confirm this finding; thus, data are conflicting regarding effects of abacavir on cardiovascular risk profile.

---

**Use In Pregnancy**

In the HHS Perinatal Guidelines section Recommendations for Use of Antiretroviral Drugs During Pregnancy (last updated October 19, 2017), **abacavir-lamivudine** is designated as a Preferred Two-NRTI Backbone in the category Preferred Initial Regimens in Pregnancy, but only for abacavir-
lamivudine should only be used in women who are HLAB*5701 negative. In addition, abacavir-lamivudine is not recommended in combination with either efavirenz or atazanavir boosted with ritonavir if the pretreatment HIV RNA is greater than 100,000 copies/mL.

- For additional information regarding the safety and toxicity of abacavir and lamivudine in pregnancy see the HHS Perinatal Guidelines summaries on Abacavir and Lamivudine.

Resistance

For a listing of the most common clinically significant mutations associated with abacavir-lamivudine (ABC-3TC) resistance, see the NRTI Resistance Notes on the Stanford University HIV Drug Resistance Database.

Key Drug Interactions

For complete information on abacavir-lamivudine-related drug interactions, see the Drug Interactions section in the Abacavir-Lamivudine (Epzicom) Prescribing Information.

No Clinical Trials Available

We do not currently have any clinical trials on file for this drug.